Journal Club with Dr. Peter Attia | Effects of Light & Dark on Mental Health & Treatments for Cancer
from Huberman Lab
by Scicomm Media
Published: Mon Jan 22 2024
Show Notes
In this journal club episode, my guest is Dr. Peter Attia, M.D., a Stanford and Johns Hopkins-trained physician focusing on healthspan and lifespan and the host of The Drive podcast.
We each present a peer-reviewed scientific paper chosen because it contains novel, interesting, and actionable data. First, we discuss a paper on how bright light exposure at sunrise and throughout the day and dark exposure at night independently improve mental health and can offset some of the major symptoms of mental health disorders such as depression and anxiety. Then, we discuss an article that explores a novel class of immunotherapy treatments to combat cancer. We also discuss some of the new data on low-calorie sweeteners and if they are safe. This episode should be of interest to listeners curious about maximizing their vitality and longevity and to anyone seeking science-supported ways to improve mental health and lifespan.
Read the full shotes for this episode at hubermanlab.com.
Thank you to our sponsors
AG1: https://drinkag1.com/huberman
LMNT: https://drinklmnt.com/hubermanlab
Timestamps
Dr. Peter Attia, Journal Club
Sponsors: LMNT & Waking Up
Light, Dark & Mental Health; Retina
Outdoor vs. Indoor Light, Cataracts, Sunglasses
Tools: Sunrise & Sunsets, Circadian Rhythm; Midday Light
Tools: Night & Light Exposure; Waking Before Sunrise
Article #1, Light/Dark Exposure & Mental Health
Sponsor: AG1
Odds Ratio, Hazard Ratio
Night vs. Daylight Exposure, Mental Health Disorders
Major Depression & Light Exposure; Error Bars & Significance
Prescriptions; Environmental & Artificial Light; Red Lights
Nighttime Light Exposure; Sleep Trackers & Belief Effects
Light Directionality, Phone, Night
Light Wavelengths & Sensors; Sunglasses
Hawthorne Effect, Reverse Causality, Genetics
Artificial Sweeteners, Appetite
Natural Light Cycles, Circadian Rhythm & Mental Health
Article #2, Immune System & Cancer
T-Cell Activation; Viruses
Autoimmunity; Cancer & Immune System Evasion
Checkpoint Inhibitors, CTLA-4
Anti-CTLA-4 Study Drug Ipilimumab, Melanoma
Patient Population, Randomization, GP100
Response Rate
Overall Survival & Response
Median Survival vs. Overall Survival, Drug Development
Gender & Dose
Adverse Events; Autoimmunity
Pancreatic Cancer; Aging & Immune System Health
Melanoma; Lynch Syndrome, Keytruda
Immunotherapy & Cancer Treatment; Melanoma Risk
Zero-Cost Support, Spotify & Apple Reviews, YouTube Feedback, Sponsors, Momentous, Social Media, Neural Network Newsletter